This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Thrombosis	P selectin (SELP; CD62P); P selectin glycoprotein ligand-1 (PSGL-1; CD162; SELPLG)	Studies in mice suggest that inhibiting PSGL-1 or its receptor SELP could help prevent cancer-associated thrombosis. Systemic PSGL-1 derived from tumor tissue can bind its receptor on vascular cells, promoting blood clotting and thromboembolic disease. In mice, infusion of a mAb targeting SELP blocked blood clotting. Next steps could include evaluating the effects of SELP mAbs in additional models of cancer-associated thrombosis.	Work unpatented; unavailable for licensing	Thomas, G.M. <i>et al. J. Exp. Med.</i> ; published online Aug. 10, 2009; doi:10.1084/jem.20082297 Contact: Christophe Dubois, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR911, Marseille, France e-mail: christophe.dubois@univmed.fr
SciBX 2(32); doi:10.1038/scibx.2009.1242 Published online Aug. 20, 2009				